News
Scientists discover potential new way to treat anxiety
Chemically modified inhibitors of the COX-2 enzyme relieve anxiety behaviors in mice by activating natural "endocannabinoids" without gastrointestinal side effects, Vanderbilt University scientists will report next week. Endocannabinoids are natural signaling molecules that activate cannabinoid receptors in the brain,...
News
GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases
GlaxoSmithKline (GSK) has increased its commitment to the GAVI Alliance to provide vaccines to developing countries, helping to protect millions more children against infectious diseases. Under this new agreement, GSK will provide an additional 240...
News
Researchers target HER1 receptor for peptide cancer vaccine, therapeutic agents
Small proteins called peptides that consist of 10 to 50 amino acids are being studied as cancer vaccines and as possibly safer, more effective and less costly alternatives to the monoclonal-antibody-based drugs and small-molecule inhibitors now used to treat...
News
Studies suggest new key to ‘switching off’ hypertension
A team of University of California, San Diego researchers has designed new compounds that mimic those naturally used by the body to regulate blood pressure. The most promising of them may literally be the key to controlling hypertension, switching...
News
New plan of attack in cancer fight
New research conducted by Harvard scientists is laying out a road map to one of the holy grails of modern medicine: a cure for cancer. As described in a paper recently published in eLife, Martin...
News
Uncovering a healthier remedy for chronic pain
Physicians and patients who are wary of addiction to pain medication and opioids may soon have a healthier and more natural alternative. A Duke University study revealed that a derivative of DHA (docosahexaenoic acid), a...
News
Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
Published in the European Journal of Heart Failure1, results from a new sub-analysis of the RE-LY®* trial demonstrate important benefits of Pradaxa® (dabigatran etexilate) over warfarin in difficult-to-treat patients with non-valvular atrial fibrillation (AF) and previous symptomatic heart failure...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















